{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:13Z","timestamp":1791995653312,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute severe ulcerative colitis (ASUC) remains a clinical challenge associated with considerable morbidity, including colectomy. Upadacitinib (UPA), a selective Janus kinase (JAK)-1 inhibitor, is approved for moderate-to-severe ulcerative colitis in patients intolerant or not responding to tumor necrosis factor-alpha inhibitors. It has also increasingly been used off-label for ASUC. We performed a systematic review of all available literature on UPA in ASUC. We identified 11 studies, with a pooled total of 55 patients. Most patients experienced rapid and sustained improvement. Colectomy rate at 90 days was 16.3%. Among those who did not get colectomy, 80% were in steroid-free remission at follow-up. The reported adverse events were low, including 2 venous thromboembolic events. Overall, UPA appears to represent a safe and effective therapy for ASUC.<\/jats:p>","DOI":"10.1093\/ibd\/izae191","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T18:06:08Z","timestamp":1724695568000},"page":"1145-1149","source":"Crossref","is-referenced-by-count":51,"title":["Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-4977","authenticated-orcid":false,"given":"John A","family":"Damianos","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufemi","family":"Osikoya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UNTHSC, Medical City , Arlington, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Brennan","sequence":"additional","affiliation":[{"name":"GI Alliance , Mansfield , TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"3","key":"2025041105235494300_CIT0001","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2025041105235494300_CIT0002","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MOG.0000000000000953","article-title":"In-hospital management of inflammatory bowel disease","volume":"39","author":"Berinstein","year":"2023","journal-title":"Curr Opin Gastroenterol."},{"issue":"3","key":"2025041105235494300_CIT0003","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"10341","key":"2025041105235494300_CIT0004","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"issue":"7","key":"2025041105235494300_CIT0005","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","volume":"119","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2025041105235494300_CIT0006","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ibd\/izae038","article-title":"Clinical outcomes at 8-16 weeks after upadacitinib initiation for acute severe ulcerative colitis: a case series in the United States","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2025041105235494300_CIT0007","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"10","key":"2025041105235494300_CIT0008","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ibd\/izad180","article-title":"Upadacitinib for acute severe ulcerative colitis","volume":"29","author":"Zinger","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"e940966","key":"2025041105235494300_CIT0009","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/AJCR.940966","article-title":"Upadacitinib as a rescue therapy in acute severe ulcerative colitis: a case report and review of the literature","volume":"24","author":"Ali","year":"2023","journal-title":"Am J Case Rep"},{"issue":"12","key":"2025041105235494300_CIT0010","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jgh3.13015","article-title":"Upadacitinib in end stage renal disease: a case of acute severe ulcerative colitis","volume":"7","author":"Hilley","year":"2023","journal-title":"JGH Open"},{"issue":"10S","key":"2025041105235494300_CIT0011","doi-asserted-by":"publisher","first-page":"S2116","DOI":"10.14309\/01.ajg.0000962320.66241.35","article-title":"S3170 JAK(1i) to the rescue! Upadacitinib as rescue therapy in acute severe ulcerative colitis","volume":"118","author":"Madej","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"12S","key":"2025041105235494300_CIT0012","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.14309\/01.ajg.0000995872.32570.7e","article-title":"S34 intestinal ultrasound to assess clinical response after induction with upadacitinib in acute severe ulcerative colitis","volume":"118","author":"Shipley","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"10S","key":"2025041105235494300_CIT0013","doi-asserted-by":"publisher","first-page":"S2138","DOI":"10.14309\/01.ajg.0000962468.27189.00","article-title":"P2231 induction of remission in TNF-alpha inhibitor refractory acute severe ulcerative colitis with upadacitinib: a case report","volume":"118","author":"Martyn","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"2025041105235494300_CIT0014","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1053\/j.gastro.2023.11.281","article-title":"Upadacitinib as second- and third-line salvage therapy for refractory acute severe ulcerative colitis","volume":"166","author":"Hassan","year":"2024","journal-title":"Gastroenterology."},{"issue":"10S","key":"2025041105235494300_CIT0015","doi-asserted-by":"publisher","first-page":"S2142","DOI":"10.14309\/01.ajg.0000962504.98929.1c","article-title":"S3216 upadacitinib - a treatment alternative for severe ulcerative colitis in the hospital","volume":"118","author":"Anand","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"9857","key":"2025041105235494300_CIT0016","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet."},{"issue":"1","key":"2025041105235494300_CIT0017","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus Ciclosporin for Steroid-Resistant Acute Severe Ulcerative Colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"10","key":"2025041105235494300_CIT0018","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/apt.17938","article-title":"Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC Study)","volume":"59","author":"Garc\u00eda","year":"2024","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae191\/58927097\/izae191.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/1145\/58927097\/izae191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/1145\/58927097\/izae191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:24:05Z","timestamp":1744349045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/4\/1145\/7742109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,26]]},"published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae191","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,8,26]]}}}